WASHINGTON -- Adding dupilumab (Dupixent) to a medium-dose inhaled corticosteroid (ICS) routine helped lower asthma exacerbations and improved both lung function and asthma control, according to a ...

Please provide your email address to receive an email when new articles are posted on . Studied patients went from a medium-dose ICS to either a high-dose ICS or biologic. Exacerbation episodes and ...

Most patients with severe asthma who were treated with the biologic therapy benralizumab were able to reduce their dose of inhaled corticosteroid (ICS), and more than half could stop steroid use ...

Please provide your email address to receive an email when new articles are posted on . 96% of patients maintained reductions through 48 weeks. 91% of patients had no exacerbations while tapering ...

MILAN -- Benralizumab (Fasenra) allowed patients with severe eosinophilic asthma to reduce inhaled corticosteroid (ISC) use without compromising control, the SHAMAL phase IV randomized trial found.

A phase 4 study found severe asthma can be controlled using biologic therapies, without the addition of high-dose inhaled steroids. Among a cohort of patients with severe asthma using the biologic ...